Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Workplace Drug and Alcohol Testing Clinic

Vancouver, British Columbia, May 4, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the delivery of its Marijuana Breath Test (“MBT”) products to a drug and alcohol testing clinic serving workplace clients in eastern Canada. The client provides drug testing and process services, delivering results to commercial companies, private businesses, government agencies and individual clients. The delivery was completed through an authorized reseller.

This delivery reflects increasing interest amongst professional testing clinics in breath‑based THC technology. This is in response to employers, regulators, and insurers seeking more relevant, timely, and defensible tools to assess recent cannabis use in workplace settings. The announcement highlights diverse industries that are adopting the Company’s non‑invasive breath‑based testing products to support workplace safety and compliance programs and occupational testing environments.

Workplace Testing Clinics Face Growing Need for Recent‑Use THC Assessment

Workplace drug and alcohol testing clinics play a critical role in helping employers meet safety, compliance, and legal obligations. However, clinics increasingly face challenges associated with cannabis policy changes, particularly the limitations of traditional testing methods.

Legacy urine and oral fluid tests can detect cannabis exposure days or weeks after use, making it difficult for clinics to provide results that meaningfully correlate with recent use. This gap creates operational, legal, and reputational risks for clinics when test results are challenged by employers, employees, unions, or legal counsel.

As a result, clinics are under pressure to adopt technologies that:

• Better align with real‑world workplace safety decision‑making
• Support post‑incident and reasonable‑cause testing
• Reduce disputes related to historical cannabis use
• Enhance the clinic’s role as a scientifically credible and neutral service provider

The Cannabix MBT offers testing clinics a new category of service designed to complement existing programs. Breath‑based THC testing provides several advantages for clinics serving regulated and safety‑sensitive workplaces:

• Short detection window aligned with recent cannabis use
• Non‑invasive collection, improving donor compliance and experience
• On‑site or in‑clinic deployment, reducing logistical burden
• Objective, lab‑confirmed results using gold‑standard LC‑MS analysis
• Reduced exposure to legal challenges associated with historical positives

By offering breath‑based testing, clinics can differentiate their service offerings while supporting employers who require actionable information tied to recent‑use timeframes.

Strategic and Investor‑Focused Outlook

Workplace drug and alcohol testing clinics represent a key adoption channel for the MBT. These clinics maintain long‑standing relationships with employers, understand jurisdictional compliance requirements, and increasingly seek technologies that enhance the relevance and credibility of their services.

Cannabix believes breath‑based THC testing can become an important adjunct standard within professional testing environments, particularly for deterrence, post‑incident, reasonable‑cause, and fitness‑for‑duty applications.